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Abstract
Background: Venous Thrombosis (VT) is a common multifactorial disease associated with a major public health burden.
Genetics factors are known to contribute to the susceptibility of the disease but how many genes are involved and their
contribution to VT risk still remain obscure. We aimed to identify genetic variants associated with VT risk.
Methodology/Principal Findings: We conducted a genome-wide association study (GWAS) based on 551,141 SNPs
genotyped in 1,542 cases and 1,110 controls. Twelve SNPs reached the genome-wide significance level of 2.061028 and
encompassed four known VT-associated loci, ABO, F5, F11 and FGG. By means of haplotype analyses, we also provided novel
arguments in favor of a role of HIVEP1, PROCR and STAB2, three loci recently hypothesized to participate in the susceptibility
to VT. However, no novel VT-associated loci came out of our GWAS. Using a recently proposed statistical methodology, we
also showed that common variants could explain about 35% of the genetic variance underlying VT susceptibility among
which 3% could be attributable to the main identified VT loci. This analysis additionally suggested that the common variants
left to be identified are not uniformly distributed across the genome and that chromosome 20, itself, could contribute to
,7% of the total genetic variance.
Conclusions/Significance: This study might also provide a valuable source of information to expand our understanding of
biological mechanisms regulating quantitative biomarkers for VT.
Citation: Germain M, Saut N, Greliche N, Dina C, Lambert J-C, et al. (2011) Genetics of Venous Thrombosis: Insights from a New Genome Wide Association
Study. PLoS ONE 6(9): e25581. doi:10.1371/journal.pone.0025581
Editor: Heribert Schunkert, Universita¨tsklinikum Schleswig-Holstein - Campus Luebeck, Germany
Received June 7, 2011; Accepted September 6, 2011; Published September 27, 2011
Copyright:  2011 Germain et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: M.G. was supported by grants funded by the Agence Nationale pour la Recherche (Project ANR-07-MRAR-021) and the Program Hospitalier de
recherche Clinique (PHRC2009 RENOVA-TV). T.O.M. was supported by a grant from the Fondation pour la Recherche Me´dicale. The MARTHA project was
supported by a grant from the Program Hospitalier de Recherche Clinique and the FARIVE study by grants from the Fondation pour la Recherche Me´dicale, the
Program Hospitalier de recherche Clinique (PHRC 20002; PHRC2009 RENOVA-TV), the Fondation de France, and the Leducq Foundation. Statistical analyses
benefit from the C2BIG computing centre funded by the Fondation pour la Recherche Me´dicale and La Re´gion Ile de France. The 3C Study is conducted under a
partnership agreement between Inserm, the Victor Segalen –Bordeaux II University and Sanofi-Synthe´labo. The Fondation pour la Recherche Me´dicale funded the
preparation and first phase of the study. The 3C-Study is also supported by the Caisse Nationale Maladie des Travailleurs Salarie´s, Direction Ge´ne´rale de la Sante´,
Mutuelle Generale de l’Education Nationale, the Institut de la Longe´vite´, Agence Franc¸aise de Se´curite´ Sanitaire des Produits de Sante´, the Regional Governments
of Aquitaine, Bourgogne and Languedoc-Roussillon and, the Fondation de France, the Ministry of Research-Inserm Programme ‘Cohorts and collection of
biological material’. The Lille Ge´nopoˆle received an unconditional grant from Eisai. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts. Funding was received from Sanofi-Synthe´labo. The Lille
Ge´nopoˆle received an unconditional grant from Eisai. There are no patents, products in development or marketed products to declare. This does not alter the
authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: david.tregouet@upmc.fr (D-AT); pierre.morange@ap-hm.fr (P-EM)
Introduction
Venous thrombosis (VT) is a common multifactorial disease
affecting two individuals out of one thousand a year and associated
with a mortality rate of 10% [1]. Recurrence risk of VT is about
6% a year, and post-thrombotic disease occurs within the next 5
years following a VT event in about 25% of patients [2]. It has
been reported that 25,000 individuals die from the consequences
of VT each year in England [3] and that the disease has a
substantial economic costs [4,5]. Despite these striking elements,
venous thrombosis can be considered as the Cinderella of genetic
research on thrombotic disorders compared to arterial and
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cerebral thrombosis. Even though genetic factors are estimated to
explain up to 60% of the VT heritability [6,7], VT genetics has
not benefit a lot from the genome wide association study (GWAS)
revolution. While several GWAS and meta-analysis of GWAS
have been conducted for arterial and cerebral thrombosis on
thousands of individuals [8–14], only one GWAS on VT has been
reported so far [15], and on a rather small sample of 419 cases and
1,228 controls. Before this GWAS was carried out, well-established
susceptibility genes for VT were SERPINC1, PROC, PROS1, FII,
FGG, FV and ABO [16]. The latter two loci were the only genomic
regions that reached genome-wide statistical significance in the VT
GWAS. Nevertheless, using additional strategies to assess the most
promising associations generated by this GWAS, other VT-
associated loci were robustly identified, HIVEP1 [17], C4BPA [18],
and TC2N [19]. Two additional VT-associated loci, GP6 and F11
[20], were also robustly identified through another large-scale
association study, focusing mainly on non-synonymous polymor-
phisms.
In our quest to identify novel susceptibility genes for VT beyond
those already known (Figure 1), we report the results of a second
GWAS based on a larger sample size (1,542 cases and 1,110
controls) and exploring a larger number of single nucleotide
polymorphisms (SNPs) (551,141 vs 317,139 in the previous GWAS
[15]). The overall sequential procedure of this work was
summarized in Figure 2. A standard GWAS comparing VT
patients participating in the MARTHA project [21] to healthy
individuals from the Three-City Study (3C) [22] was first
performed to identify genome-wide significant associations of
SNPs with VT risk (stage I). Second, results from this GWAS were
combined to those of our previously published GWAS on VT
(referred to as ‘‘in silico GWAS’’ in the rest of the document) [15]
to detect novel associations that would not have been declared
significant at stage I. At this stage (stage II), both raw and imputed
genotyped data analyses were carried out. In addition to this
standard GWAS, we performed a candidate gene association
analysis using less stringent statistical thresholds. SNPs demon-
strating suggestive evidence of association with the disease were
then planned to be further tested for replication in independent
case-controls studies. A new estimate of the genetic variance
associated with VT susceptibility was also derived using a novel
methodology for GWAS data.
Results
Genome Wide Association analysis
Stage I. A quantile-quantile (Q-Q) plot representation of the
whole set of association results was compatible with what was
expected under the assumption of no genetic association (Figure 3)
and the corresponding genomic control (GC) value was 1.04.
Among the 491,258 tested SNPs at this stage, twelve were
significant at the fixed genome-wide threshold of p,2.061028
(Table 1). These SNPs were located within ABO, FGG, F5, and F11
loci, four well-established VT-associated genes. The F5 and ABO
hit SNPs included those already identified in our previous GWAS
[15] while the FGG VT-associated SNP was the rs2066865,
located in the 39UTR region of the gene and known to influence
both fibrinogen c9 levels and VT risk [15,23,24]. The F11 hit SNP
was the rs10029715. According to the SNAP software [25] based
on HapMap 3 (release 2), this SNP is in modest linkage
disequilibrium (LD) with two F11 SNPs recently found to
independently affect VT risk [20,26], rs2036914 and rs2289252
(r2 = 0.094, D9= +0.66, and r2 = 0.076; D9=+0.75, respectively).
However, these two SNPs were not available in our genotyping
array. Several other F11 SNPs showed suggestive statistical
associations with VT at p,1024 (Table S1) and their haplotype
analysis showed that the F11 association signal was driven by two
common yin/yang haplotypes (Table 2). We then used the
HapMap data to infer the F11 haplotypic structure derived from
the two rs2036914 and rs2289252 SNPs and those found
associated with VT in our sample. It is interesting to note that
the yin-yang pattern described above is still present when the
rs2036914 and rs2289252 are included in the analysis (Table S2).
Stage II. The results of the new GWAS were combined to
those obtained on the previous in silico GWAS [15] through a
meta-analysis totaling 1,961 VT cases and 2,238 controls. Using
either the 253,355 genotyped SNPs common to both GWAS
studies or 2,475,305 observed or imputed SNPs, no novel
association was detected (Figure 4). In the imputation analysis,
only 99 SNPs reached genome-wide significance and they were all
located within the ABO, F5, FGG, or F11 loci (Table S3). Detailed
regional association plots for these four loci are shown in Figure 5.
Candidate Gene association analysis
We then further explored the association results obtained in the
discovery GWAS by focusing on SNPs located within candidate
genes as it is now well-admitted that genuine association may be
hidden in the heap of non genome-wide significant associations.
Forty-nine genes were selected as candidates because they were
either known to participate to the coagulation/fibrinolysis cascade,
were already shown to be associated with VT , or had recently
been identified through GWAS as modulating the variability of
quantitative traits known/hypothesized to be associated with VT
risk (Table S1).
In addition to the genome-wide significant loci discussed above,
four candidate loci were found to harbor SNPs showing suggesting
evidence of association with VT at p,1023 (Table S1). These
SNPs were rs169715 and rs2228220 in HIVEP1, rs6060278 and
rs6088735 in PROCR, rs4981021 in STAB2 and rs8074026 in
SERPINF2.
The two HIVEP1 SNPs, rs169715 and rs2228220, were in
modest LD with each other (r2 = 0.09, D9=+0.45). Their
haplotype analysis suggested that the observed effects would be
additive (Table 3), the rs169715-G allele being associated with an
adjusted OR of 1.57 [1.17–2.09] (p = 2.60 1023) and the
rs2228220-G allele with an OR of 1.35 [1.10–1.66] (p = 3.98
1023). In addition, this haplotype analysis suggested that the effect
Figure 1. Known candidate loci for VT.
doi:10.1371/journal.pone.0025581.g001
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on VT risk of the previously identified HIVEP1 rs169713 [17] was
due to its LD with the rs169713 (r2 = 0.01, D9=1) and rs2228220
(r2 = 0.06, D9=20.50) HIVEP1 hit SNPs (Table 3).
The two PROCR SNPs, rs6060278 and rs6088735, were in
complete association (r2 = 1) and were also in strong negative LD
(r2 = 0.03, D9=21) with the rs867186 variant, also known as
Ser219Gly. The role of the latter in VT risk is still a matter of
debate [15] and its association with VT was borderline in our
discovery GWAS (Table S1). Nevertheless, a haplotype analysis of
the rs6088735 and rs867186 suggested that both SNPs could act
additively on the risk of disease (Table 4). When adjusted for
rs6088735, the rs867186-G allele was associated with an OR for
VT of 1.33 [1.11–1.60] (p = 2.34 1023) whereas , adjusted for
rs867816, the rs6088735-T allele was associated with an OR of
1.35 [1.19–1.54] (p = 5.47 1026) (Table 4). Interestingly, according
to the SNAP database [25], the rs6088735 is in complete
association (r2 = 1) with the EDEM2 rs6120849 that was recently
found associated with protein C levels in the ARIC study [27].
The rs6088735-T allele associated with increased risk of VT
corresponds to the rs6120849-T allele that was associated with
decreased protein C levels, an observation consistent with the
known association of decreased PROC levels and VT risk [28].
The STAB2 rs4981021-T allele was associated with increased
risk of VT 1.29 [1.14–1.46] (p = 3.17 1024) but this association did
not reach significance (OR=1.10, p = 0.251) in the ‘‘in silico
GWAS’’. Conversely, the most significant STAB2 SNP in the latter
study was the rs1593812 already discussed in [29]. Haplotype
analysis of these two SNPs suggested that they define at least one
common at-risk haplotype for VT in both GWAS datasets
(OR=2.18 [1.66–2.87] (p = 2.16 1028) (Table 5). Note that the
rs4981021-T is a good proxy (r2 = 0.88) for the rs12229292-T not
typed in our GWAS array but recently found associated with
increased Factor VIII levels [30].
The association observed at SERPINF2 was novel, the
rs8074026-T allele being more frequent in MARTHA cases than
in 3C healthy controls (0.29 vs 0.24, p= 6.87 1024). This SNP was
not typed in our previous GWAS in patients with early age of
onset of VT but a similar trend was observed using imputation
data (0.22 vs 0.19, p = 0.289). This SNP was therefore further
explored in the FARIVE study, but the association was not
confirmed as the rs8074026-T allele tended, conversely, to be less
frequent in cases than in controls (0.23 vs 0.25, p = 0.520). This
polymorphism was then not further studied.
Genetic variance analysis
The next step of our analysis consisted in getting an overall
estimate of the genetic variance (h2) of VT as well as an estimate of
the contribution of the main susceptibility loci discussed above.
The application of the GCTA software [31] to the discovery
GWAS led to an estimate of 0.35760.049. This estimate was
obtained using an assumed prevalence of 0.001 for the disease
according to [1]. This estimate was strongly dependent on the
value of the assumed prevalence (Table 6). When the GCTA
analysis was applied to the first GWAS data set with an assumed
prevalence of 0.001, the genetic variance estimate was 0.223 with
a larger standard error, 0.108, an estimate that was nevertheless
consistent with that observed in the discovery GWAS.
The relative contribution of each chromosome is summarized in
Figure 6 for a prevalence of 0.001. While F5 and ABO explained
,1%, each, of the genetic variance, and the FGG and F11 together
only 1.2%, we note that the chromosome most contributing to the
estimate (6.9%61.2) was chromosome 20. This observation hold
whatever the assumed value for the prevalence of VT (Table 6).
We then turned back to the original GWAS results and focused on
chromosome 20 SNPs. Only eleven chromosome 20 SNPs
Figure 2. Main outlines of the adopted sequential GWAS strategy.
doi:10.1371/journal.pone.0025581.g002
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Table 1. Stage I - Minor allele frequencies distribution of SNPs demonstrating association with VT at pEIGENSTRAT,2.0 10
28 in a
GWAS sample of 1,542 VT cases and 1,110 controls.
CHR Position Gene SNP Alleles(1) Cases Controls P(2) P(3)
1 167401751 NME7 rs16861990 C/A 0.134 0.058 5.53610220 2.75610215
1 167695568 SLC19A2 rs1208134 C/T 0.133 0.056 4.06610221 3.29610216
1 167758179 F5 rs2420371 G/A 0.151 0.066 3.24610223 8.44610219
4 155744726 FGG rs2066865 A/G 0.280 0.209 3.4461029 1.17610210
4 155720638 FGA rs6825454 C/T 0.299 0.228 1.3961028 1.3261029
4 187459594 F11 rs10029715 C/T 0.115 0.172 1.0961029 3.2061029
9 135126961 ABO rs2073828 A/G 0.321 0.406 1.91610210 3.5761029
9 135129086 ABO rs657152 C/A 0.494 0.383 5.55610220 1.10610218
9 135138468 ABO rs500498 T/C 0.332 0.432 3.54610214 1.03610212
9 135139050 ABO rs505922 C/T 0.489 0.350 1.53610225 1.06610223
9 135139543 ABO rs630014 A/G 0.381 0.485 9.26610215 4.40610214
9 135144688 ABO rs495828 T/G 0.357 0.264 8.82610213 1.78610214
(1)Common/minor alleles.
(2)P-value of the Cochran-Armitage Trend test.
(3)Association test p-value corrected for principal components (EIGENSTRAT program).
doi:10.1371/journal.pone.0025581.t001
Figure 3. Quantile-Quantile plot representation of the GWAS results obtained from 491,258 studied SNPs. Q-Q plot derived from all
SNP p-values is illustrated by + . The exclusion of 878 SNPs located within6500 kb of the ABO, F5, FGG and FXI loci, the four main well-established VT-
associated loci, lead to the Q-Q plot symbolized by # with its 95% confidence interval in shaded area.
doi:10.1371/journal.pone.0025581.g003
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corresponding to four different loci RSPO4, C20orf23/SNRPB2,
MYLK2 and PREX1, showed association at p,1024 with VT
(Table 7). We further investigated whether these four loci, in
addition to the PROCR locus mentioned above that was also
located on chromosome 20, could substantially contribute to
explain the genetic variance contribution of chromosome 20. After
discarding the genetic influence of these five loci, the remaining
estimate associated with chromosome 20 SNPs was 5.5%61.2.
Further analyses also suggested that ,80% of the chromosome
20’s contribution came from SNPs located in its 20p arm (Table 6).
Discussion
In this work we reported the results of a second GWAS on VT
that, when added to the previous one, gathered a total sample of
1,961 cases and 2,338 controls, all of French origin. With such a
sample size, our study had a power of 80% at the genome-wide
significance level of ,261028 to detect the allelic effect of any
SNP associated with an OR of 1.40 provided that its minor allele
frequency is greater than 0.20 [32]. These values perfectly
matched those observed at the four loci (F5, FGG, F11 and ABO)
that reached genome-wide significant in this report (Table S3),
these four loci being now well-established susceptibility genes to
VT [15,16,26]. The contribution of F5 and ABO in VT
susceptibility has been extensively discussed and the functional
role of FGG rs2066865 has already been established [3,23,24].
Conversely, the identification of the functional F11 variant(s)
hypothesized to be tagged by the ying/yang haplotype structure
discussed above deserves additional work.
In order to achieve a 80% power for detecting ORs of
magnitude 1.30, 1.25 and 1.20, the statistical stringency would
have to be lessened to 361025, 661024, and 961022,
respectively, at the risk of increasing false positive rates. In an
attempt to increase the power of our analysis while limiting for
false positives, we therefore focused on all SNPs located within
,fifty candidate genes and demonstrating suggestive statistical
evidence (p,1024) for association with VT using raw genotype
data. Suggestive associations were observed for the HIVEP1,
PROCR, STAB2 and SERPINF2 loci (Table S1). Associations with
VT have already been reported for the first three genes [15,17,29]
and disentangling their exact genetic contribution to VT
susceptibility would warrant additional extensive works. The latest
suggestive association was observed for the SERPINF2 rs8074026.
SERPINF2 is an obvious candidate for VT as it codes for a serpine
protease inhibitor that acts as a inhibitor of plasmin. However, no
trend for association was observed in the replication study.
Following the findings of a GWAS on aPTT levels [33], a
candidate biomarker for VT, we have recently suggested that the
Table 2. Haplotype association analysis of F11 hit SNPs with
VT risk in a sample of 1,542 VT cases and 1,110 controls.
Polymorphisms
Haplotype
Frequencies
rs925451 rs10029715 rs1008728 rs13133050 Controls Cases
n=1110 n=1542
A T T C 0.338 0.403
A T C A 0.033 0.027
A C C C 0.016 0.011
G T T C 0.257 0.248
G T C A 0.196 0.201
G C C C 0.043 0.041
G C C A 0.106 0.051
F11 haplotypes were more strongly associated with VT (p = 1.05 10212) than
single SNP alone (best p-value = 1.09 1029) and the association was likely due to
two common haplotypes, ATTC and GCCA, differing at all studied sites (‘‘yin-
yang’’ haplotypes), the former being associated with increased risk of VT, the
latter with decreased risk. Compared to the GTTC haplotype, the ATTC
haplotype was associated with an increased risk of VT (OR = 1.218 [1.048–1.416],
p = 0.0099 while the GCCA haplotype was associated with a decreased risk of
the disease (OR= 0.493 [0.391–0.623], p = 3.39 1029).
doi:10.1371/journal.pone.0025581.t002
Figure 4. Manhattan plot of the association results from the combined analysis of two imputed GWAS data sets for 2,475,305 SNPs.
doi:10.1371/journal.pone.0025581.g004
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KNG1 Ile581Thr variant (rs710446) could also be a risk factor for
VT using data from our discovery GWAS and the FARIVE
studies. This variant only reached a significance of p = 1.17 1023
in the discovery GWAS (Table S1) highlighting the need for
exploring in more details the list of less significant p-values, in
particular by use of external information on candidate quantitative
risk factors. Two other SNPs have recently been suggested to
influence VT-risk, STXBP5 rs1039084 and VWF rs1063856 [34].
These were not available in the ‘‘in silico’’ GWAS, but using QC
imputed data in the whole set of 1,961 cases and 2,338 controls,
the rare allele of the VWF rs1063856 was marginally associated
with the risk of VT (OR=1.10 [1.00–1.21], p = 0.042) , an
association consistent with that previously reported [34]. Con-
versely, we did not observe any trend of association for the
STXBP5 rs1039084 rare allele (OR=0.97 [0.89–1.06]; p = 0.55),
even if this OR was of similar amplitude with that observed in the
MEGA study (OR=0.91 [0.86–0.97]) [34]. These two associa-
tions were previously observed in a meta-analysis of studies
gathering about 5,000 cases and 5,000 controls, underlying the
low power of our study to detect modest genetic effect as already
discussed above. Large GWAS samples gathering at least ,20,000
patients would be required in order to detect genome-wide
significant ORs of ,1.10 and, for the moment, we are far from
reaching such sample size by contrast to international consortia on
coronary artery disease [35] . Another limitation of this work could
be related to the selection of the GWAS subjects. Controls were
part of a national GWAS sample of French healthy individuals
that were not matched to VT cases, in particular for gender and
sex. Nevertheless, all known or suspected VT-associated loci were
identified in our work suggesting a rather modest influence of
imperfect matching between cases and controls. Conversely, VT
patients homozygous for the FV Leiden or FII 20210A mutation
or with anti-thrombin, protein C or protein S deficiencies were not
included in this work. It is very unlikely that the selection on FV
Leiden homozygosity had affected our results as the F5 gene is
among the four loci that reached genome-wide significance in our
study. Note that the FII 20210 mutation (rs1799963) was not
available in the imputed reference datasets. However, one cannot
exclude that the other exclusion criteria may have affect our power
to identify novel VT-associated variants, in particular through a
Figure 5. Regional association plots at the four genome-wide significant loci using imputed SNPs. Four genome-wide significant loci
were F5 (top left), FGG (top right), F11 (bottom left) and ABO (bottom right). These plots were drawn from the SNAP software [25].
doi:10.1371/journal.pone.0025581.g005
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modulation of anti-thrombiin, protein C or protein S levels. It is
nevertheless worthy of note that the PROCR locus that was found
influencing the most protein C levels in the ARIC GWAS [27],
was among the top 8 most significant VT-associated loci in our
GWAS.
The second original aspect of our work is the application of a
novel statistical methodology to get an estimate of the genetic
variance of VT. This approach requires several assumptions
including a fixed value for the disease prevalence, additive genetic
effects and the existence of an underlying liability characterized by
a threshold above which the disease status is called. Using the
latest known estimate of the VT prevalence [1], we showed that
the genetic variance could be ,35%, an estimate slightly lower
than those obtained from families studies [6,7]. While the four
main VT-linked loci, FV, ABO, FGG and F11, altogether
contributed to about ,3% of the total genetic variance it was
striking to observe that chromosome 20 was the chromosome
contributing the most to the total genetic variance with about
,7% of the total genetic variance. Further analyses including
chromosome-wide haplotype and homozygosity mapping analyses
are ongoing to further investigate the chromosome 20 genetic
architecture in relation to VT risk.
In conclusion, this work provided new information about the
genetic susceptibility to VT and strongly suggested that chromo-
some 20 genes warrant specific attentions. It generated a wealth of
valuable genetic information to those showing interest in
disentangling the genetic architecture of VT.
Materials and Methods
Ethics Statement
Each individual study was approved by its institutional ethics
committee and informed written consent was obtained in
accordance with the Declaration of Helsinki. All subjects were of
European origin. All subjects were of European origin.
Ethics approval were obtained :
N for MARTHA, from the ‘‘Departement sante´ de la direction
ge´ne´rale de la recherche et de l’innovation du ministe`re’’
(Projects DC: 2008-880 & 09.576).
N for FARIVE, from the ‘‘Comite´ consultatif de protection des
personnes dans la recherche biomedicale’’ (Project nu 2002-
034)
N for the 3C study, from the institutional ethics committees of the
Kremlin-Bicetre Hospital.
Studies
Stage I - Discovery GWAS. MARTHA patients (n = 1,592)
are unrelated VT patients, mainly of French origin, consecutively
recruited at the Thrombophilia center of La Timone hospital
(Marseille, France) between January 1994 and October 2005. All
patients had a history of a first VT event documented by
venography, Doppler ultrasound, angiography and/or
ventilation/perfusion lung scan. They were all free of any
chronic conditions and free of any well characterized genetic
risk factors including anti-thrombin, protein C or protein S
deficiency, homozygosity for FV Leiden or FII 20210A, and lupus
anticoagulant. A more detailed description of these patients can be
found in [21]. These VT patients were compared to healthy
individuals from the 3C study.
Table 3. Haplotype analysis of HIVEP1 haplotypes derived
from rs169713, rs169715 and rs2228220 in a sample of 1,542
cases and 1,110 controls.
Polymorphisms Haplotype Frequencies
rs169713 rs169715 rs2228220 Controls Cases
n=1,110 n=1,542
C A A 0.198 0.206
C A G 0.042 0.054
T A A 0.698 0.643
T A G 0.026 0.037
T G A 0.018 0.027
T G G 0.017 0.031
HIVEP1 haplotypes were strongly associated with VT risk (x2 = 30.22 with 5df,
p = 1.33 1025).
All haplotypes carrying the rs169715-G or the rs2228220-G alleles tended to be
more frequent in cases than in controls, suggesting that both alleles could act
additively to influence VT risk. This hypothesis were then tested and was not
rejected (x2 = 0.75 with 2 df, p = 0.686). After adjusting for rs2228220, the OR
associated with the rs169715-G allele was 1.57 [1.17–2.09] (p = 2.60 1023) and
the OR associated with rs2228220-G adjusted for rs169715 was 1.35 [1.10–1.66]
(p = 3.98 1023). After adjusting for these two SNPs, the rs169713-C allele was
not significant (OR= 1.11 [0.97–1.26], p = 0.129).
doi:10.1371/journal.pone.0025581.t003
Table 4. Haplotype analysis of PROCR haplotypes derived
from rs6088735 and rs867186 in a sample of 1,542 cases and
1,110 controls.
Polymorphisms Haplotype Frequencies
rs6088735 rs867186 Controls Cases
n=1,110 n=1,542
C A 0.673 0.603
C G 0.095 0.115
T A 0.232 0.282
PROCR haplotypes were strongly associated with VT risk (x2 = 26.51 with 2 df,
p = 1.75 1026). Compared to the most frequent CA haplotype, the CG and TA
haplotypes were associated with an increased OR for VT of 1.33 [1.11–1.60]
(p = 2.34 1023) and 1.35 [1.19–1.54] (p = 5.47 1026).
doi:10.1371/journal.pone.0025581.t004
Table 5. Haplotype analysis of STAB2 haplotypes derived
from rs1593812 and rs4981021 in two GWAS data sets.
Polymorphisms Haplotype Frequencies
‘‘in silico GWAS’’ Discovery GWAS
rs1593812 rs4981021 Controls Cases Control Cases
n=1,228 n=419 n=1,110 n=1,542
A C 0.629 0.573 0.646 0.587
A T 0.248 0.240 0.219 0.246
G C 0.091 0.114 0.104 0.111
G T 0.032 0.073 0.031 0.056
Compared to the most frequent AC haplotype, the GT haplotype was
associated with an increased risk of 2.43 [1.60–3.71] (p = 3.0 1025) and 2.01
[1.40–2.88] (p = 1.48 1024) in the ‘‘In silico’’ and discovery GWAS respectively.
The combined Mantel-Haenszel OR associated with the GT haplotype compared
to the AC haplotype was then 2.18 [1.66–2.87] (p = 2.16 1028).
doi:10.1371/journal.pone.0025581.t005
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The 3C Study is a population-based, prospective (4-years
follow-up) study, initially set-up to investigate the relationship
between vascular factors and dementia. It has been carried out in
three French cities: Bordeaux (southwest France), Montpellier
(southeast France) and Dijon (central eastern France). A sample of
non-institutionalised subjects aged over 65 was randomly selected
from the electoral rolls of each city. Between January 1999 and
March 2001, 9,686 subjects meeting the inclusion criteria agreed
to participate. Following recruitment, 392 subjects withdrew from
the study. Thus, 9,294 subjects were finally included in the study
(2,104 in Bordeaux, 4,931 in Dijon and 2,259 in Montpellier). At
the baseline clinical examination, blood samples were obtained
from 8,707 individuals. For the present study, a random sample of
1,140 subjects free of any chronic diseases was selected to serve as
controls.
Stage II - In silico GWAS study. In a previously published
GWAS on VT [15], 419 early age of onset (,50 years) VT cases
were compared to 1,228 healthy controls at 291,872 SNPs. Cases
were patients from four different French medical centers
(Grenoble, Marseille, Montpellier, Paris) selected according to
the same criteria as the MARTHA patients, except with the
restriction on age of onset. Controls were French subjects selected
from the SUVIMAX population [36].
Stage III - Replication studies. For the replication of the
GWAS findings, the FARIVE study [15], a multicenter case-
control study for first episode of VT composed of 607 cases and
607 healthy individuals, all of French origin, was used.
Genotyping and Quality control
Stage I - Discovery GWAS. A subsample of 1011 VT
patients were typed with the Illumina Human 610-Quad Beadchip
while the remaining 586 VT patients were typed with the Illumina
Human660W-Quad Beadchip. Individuals from the 3C study
were also typed with Illumina Human 610-Quad Beadchip. A set
of 551,141 SNPs including 537,883 autosomal SNPs and 13,258
sex-linked SNPs was common to the three samples.
Individuals with genotyping success lower than 95% (n= 18)
were excluded from the analyses as were individuals demonstrat-
ing close relatedness (n = 67). This latter was assessed by pairwise
clustering of identity by state distance (IBS) and multi-dimensional
scaling (MDS) using the PLINK software [37]. The Eigenstrat
program [38] was further used to detect individuals of non-
European ancestry. SNPs showing significant (p,1025) deviation
from Hardy-Weinberg Equilibrium (HWE) in controls, with minor
allele frequency (MAF) less than 1% in the combined cases/
controls samples or genotyping call rate ,99% were filtered out.
This lead to the final analysis of 481,002 autosomal and 10,256
sex-linked SNPs in a sample of 1,542 VT patients and 1110
healthy individuals.
Stage II - In silico GWAS study. Individuals participating in
this previous GWAS were genotyped for 317,139 SNPs using the
Illumina Sentrix HumanHap300 Beadchip among which 291,872
satisfied the quality control criteria previously described [15].
Individuals of non European ancestry had been also excluded
from this analysis [15].
Stage III - Replication studies. In FARIVE, the rs8074026
was genotyped by allele-specific PCR (also referred to as ARMS i.e
amplification refractory mutation system) with success rate of
97.5%.
Statistical Analysis
Genome-wide association study. Genome-wide association
analysis of autosomal SNPs was conducted using the Eigenstrat
program that correct for any uncontrolled population stratification
[38]. The genomic control (GC) inflation factor was also computed
according to the median test statistic [39]. X-linked SNPs
association was tested using the PLINK software [37] while
adjusting for first four principal components.
Haplotype analysis. To handle the linkage disequilibrium
(LD) between SNPs of interest at specific loci, haplotype analysis
was performed by use of the THESIAS program [40].
Imputation. In both GWAS datasets, imputation of
2,557,252 autosomal SNPs was conducted using the MACH
(v1.0.16a) software (http://www.sph.umich.edu/csg/abecasis/
mach/) according to the CEU HapMap 2 release 21 (build 35)
reference dataset. A logistic regression analysis was then conducted
to evaluate the association of each SNP with VT risk in an additive
genetic model, in which allele dosage (0 to 2 copies of the minor
allele) of imputed SNPs was analyzed. Analyses were adjusted for
the first four principal components and were performed using the
mach2dat (v 1.08.18) software (http://genome.sph.umich.edu/
wki/Minimac).
Table 6. Relative contribution of each chromosome on the
total genetic variance of VT according to the assumed
prevalence of the disease.
prevalence
0.001 0.005 0.01 0.05
Total Genetic 0.357 0.480 0.561 0.860
Variance ± SE ±0.047 ±0.067 ±0.078 ±0.120
chromosome
1 0.016 0.033 0.038 0.036
2 0.015 0.020 0.023 0.036
3 0.019 0.026 0.031 0.045
4 0.041 0.052 0.060 0.094
5 0.013 0.017 0.020 0.029
6 0.006 0.012 0.014 0.016
7 0.011 0.012 0.014 0.027
8 0.004 0.021 0.025 0.010
9 0.039 0.049 0.058 0.089
10 0.040 0.042 0.049 0.094
11 0.007 0.000 0.002 0.013
12 0.020 0.018 0.022 0.047
13 0.008 0.009 0.010 0.019
14 0.002 0.017 0.019 0.003
15 0.017 0.021 0.024 0.039
16 0.007 0.010 0.012 0.016
17 0.006 0.004 0.005 0.015
18 0.008 0.008 0.010 0.017
19 0.001 0.017 0.020 0.037
20 0.069(a) 0.081 0.094 0.159
21 0.008 0.009 0.011 0.019
22 0.000 0.000 0.000 0.000
Estimates were obtained from the discovery GWAS data and adjusted for
gender and principal components.
(a)When chromosome 20 SNP data were split into two parts, one including 6,769
SNPs on the shortest 20p arm and the other 7,170 SNPs on the longest 20q
arm, their relative contribution on the genetic variance were 0.05660.013 and
0.01360.007.
doi:10.1371/journal.pone.0025581.t006
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Meta-Analysis. All SNPs with acceptable imputation quality
(r2$0.3) in both imputed GWAS datasets were entered into a
meta-analysis, leading to 2,475,305 SNPs left for statistical
association analysis. For the meta-analysis, a fixed-effect model
relying on the inverse-variance weighting was used as
implemented in the METAL software (http://www.sph.umich.
edu/csg/abecasis/metal). Homogeneity of associations across the
two GWAS studies was tested using the Mantel-Haenszel method
[41].
For all these GWAS analyses, a statistical threshold of 2.061028
was used to declare genome-wide significance. This value
corresponds to the family-wise error rate of 0.05 corrected for
the number of studied SNPs (2,475,305) according to Bonferroni
correction.
Replication. Association of SNPs tested for replication with
VT was assessed by use of the Cochran-Armitage trend test [42].
Logistic regression analysis was further used to estimate genetic
effects, expressed in terms of Odds Ratio (OR), adjusted for age,
gender, FV leiden and ABO blood group.
Genetic Variance Estimation. The recently proposed
GCTA methodology was used to investigate the genetic variance
of VT [31,43]. Briefly, this method consists in estimating the
genetic relationship between unrelated individuals from genome-
wide SNPs information and in incorporating it into a regression
model to provide an estimate of the genetic variance of a given
phenotype. For a binary phenotype such as VT, it assumes the
existence of an underlying normally distributed liability variable,
with individuals being affected if their liability exceeds a threshold
which may depends on covariates such as gender. We computed
the genetic relationships separately from all SNPs of a given
chromosome and assessed the contribution of each chromosome
on the genetic variance. A similar approach was applied to
estimate the contribution of specific loci of using all SNPs within
65 Mb of each locus. All analyses were adjusted for gender and
Table 7. Minor allele frequencies distribution of chromosome 20 SNPs demonstrating association with VT at
pEIGENSTRAT,1.00610
24 in a GWAS sample of 1,542 VT cases and 1,110 controls.
CHR Position Gene SNP Alleles(1) Cases Controls P(2)
20 960026 RSPO4 rs11696364 C/A 0.059 0.102 1.5361026
20 16273269 C20orf23 rs4814475 G/A 0.181 0.228 3.9861025
20 16312593 C20orf23 rs6034465 C/T 0.158 0.204 6.7361026
20 16574082 C20orf23 rs964216 C/T 0.116 0.084 4.5561025
20 16575913 C20orf23 rs13038362 A/C 0.114 0.084 7.4161025
20 16580409 SNRPB2 rs6135823 T/C 0.115 0.083 5.3861025
20 29886239 MYLK2 rs17340555 T/C 0.110 0.084 4.5361025
20 46604745 PREX1 rs1883888 G/A 0.350 0.286 1.1161025
20 46613060 PREX1 rs878198 A/C 0.354 0.292 3.6761025
20 46622891 PREX1 rs4810820 T/C 0.364 0.306 9.9561025
20 46624742 PREX1 rs6012481 C/T 0.345 0.287 2.7161025
(1)Common/minor alleles.
(2)Association test p-value corrected for principal components (EIGENSTRAT program).
doi:10.1371/journal.pone.0025581.t007
Figure 6. Distribution of VT genetic variance across chromosomes. In light grey is shown the relative contribution of specific loci.
doi:10.1371/journal.pone.0025581.g006
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principal components as indicated in the GCTA documentation
[31].
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Table S1 Allele frequencies of candidate gene SNPs in
the discovery GWAS sample of 1,542 VT cases and 1,110
controls. (1) Common/minor alleles. (2)Association test p-value
corrected for principal components (EIGENSTRAT program). (3)
P-value of the Cochran-Armitage Trend test corrected for the
genomic control factor. Genes were selected as candidates for VT
because either: - (A): they belong to the coagulation cascade (Blood
2000; 95:1517–1532;Blood 2008; 112: 19–27). - (B): or they belong
to the fibrinolytic cascade (Blood 2000; 95:1517–1532; Semin
Thromb Hemost. 2009;35:468–77). - (C): or they harbours SNPs
that have been associated with VT risk (Blood 2010; 115:4644–
4650; JAMA 2008; 299:1306–1314; Am J Hum Genet 2010;
86:592–595; J Thromb Haemost 2010; 8:2671–2679). - (D): or
they mapped loci found through recent GWAS associated with
quantitative biomarkers of VT such as D1: vWF & FVIII
(Circulation 2010; 121:1382–1392). D2: Platelet volume (Am J
Hum Genet 2009; 84:66–71). D3: Protein C levels (Blood 2010;
116:5032–5036). D4: aPTT (Am J Hum Genet 2010; 86:626–
631). D5: PAI-1 levels (Blood 2010; 116:2160–2163).
(DOC)
Table S2 Haplotype structure derived from VT-associ-
ated F11 SNPs in the HapMap database. Haplotype
frequencies were estimated using the Haploview software from
the HapMap 3 (release 2) data. SNPs identified in the LETS study
(Li Y et al. J Thromb Haemost 2009;7:1802–1808) are shown in
bold, others were those identified in the current MARTHA
project.
(DOC)
Table S3 Stage II - Genome-wide significant (p,2.01
1028) SNP imputed associations with VT in the com-
bined discovery and in silico GWASes of 1,961 cases and
2,338 controls. (1) Common/rare alleles. (2) Minor allele
frequency. (3) Odds Ratio associated with the minor allele
estimated from the Mach2dat imputation software, after adjusting
for principal components. (4) Combined p-values computed using
the inverse-variance model as implemented in METAL software.
All shown imputed SNPs satisfied the imputation quality criteria
(r2.hat.0.3).
(DOC)
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